Brief: Rocket Pharmaceuticals Announces Positive Clinical Safety Update From Initial Three Patients Treated With Rp-A501 Under Modified Phase 2 Protocol For Danon Disease
03/08/2026 14:22
BRIEF-Rocket Pharmaceuticals Announces Positive Clinical Safety Update From Initial Three Patients Treated With Rp-A501 Under Modified Phase 2 Protocol For Danon Disease Aug 3 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O:
ROCKET PHARMACEUTICALS ANNOUNCES POSITIVE CLINICAL SAFETY UPDATE FROM INITIAL THREE PATIENTS TREATED WITH RP-A501 UNDER MODIFIED PHASE 2 PROTOCOL FOR DANON DISEASE
ROCKET PHARMACEUTICALS - RP-A501 WELL-TOLERATED IN INITIAL THREE PATIENTS WITH NO TMA OR CAPILLARY LEAK SYNDROME
ROCKET PHARMACEUTICALS - ENGAGING WITH FDA ON PIVOTAL TRIAL; REGULATORY UPDATE EXPECTED IN H2 2026
ROCKET PHARMACEUTICALS - DANON DISEASE PROGRAM UPDATE EXPECTED IN H2 2026
Source text: ID:nBw9cyXvYa
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08